The Federal Trade Commission has accused New York’s state-level "shield law" of obstructing a federal investigation into transgender healthcare practices, arguing the legislation limits access to critical records and evidence. The dispute centers on whether the law’s protections for patient privacy conflict with broader efforts to examine potential violations in medical treatment standards. Legal challenges could determine how far states can shield sensitive health data while federal agencies pursue oversight. The case highlights growing tensions between state privacy measures and federal regulatory authority in healthcare.
FTC says New York's 'shield law' is interfering with US transgender care probe Reuters
